LDL-C and TC lowering was significantly greater in the evening dose than in the morning dose in case of short-acting statins .
Besides slight but significant effect on LDL-C , the efficacy of long-acting statins was equivalent for both regimens .
BACKGROUND Evidence about the optimal time of day at which to administer statins is lacking .
OBJECTIVE The objective of this study is to synthesize evidence about effects of morning vs evening statin administration on lipid profile .
Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.
AIMS To compare the lipid-regulating effects and steady-state pharmacokinetics of rosuvastatin , a new synthetic hydroxy methylglutaryl-coenzyme A ( HMG-CoA ) reductase inhibitor , following repeated morning and evening administration in volunteers with fasting serum low-density lipoprotein cholesterol ( LDL-C ) concentrations < 4.14 mmol l-1 . METHODS In this open-label two-way crossover trial 24 healthy adult volunteers were r and omized to receive rosuvastatin 10 mg orally each morning ( 07.00 h ) or evening ( 18.00 h ) for 14 days . After a 4 week washout period , volunteers received the alternative regimen for 14 days . Rosuvastatin was administered in the absence of food . RESULTS Reductions from baseline in serum concentrations of LDL-C ( -41.3%[morning]vs-44.2%[evening ] ) , total cholesterol ( -30.9%vs-31.8 % ) , triglycerides ( -17.1%vs-22.7 % ) , and apolipoprotein B ( -32.4%vs-35.3 % ) were similar following morning and evening administration . AUC(0,24 h ) for plasma mevalonic acid ( MVA ) , an in vivo marker of HMG-CoA reductase activity , decreased by -29.9 % ( morning ) vs-32.6 % ( evening ) . Urinary excretion of MVA declined by -33.6 % ( morning ) vs-29.2 % ( evening ) . The steady-state pharmacokinetics of  rosuvastatin were very similar following the morning and evening dosing regimens . The Cmax values were 4.58 vs 4.54 ng ml-1 , and AUC(0,24 h ) values were 40.1 vs 42.7 ng ml-1 h , following morning and evening administration , respectively . There were no serious adverse events during the trial , and rosuvastatin was well tolerated after morning and evening administration . CONCLUSIONS The pharmacodynamic effects and pharmacokinetics of rosuvastatin are not dependent on time of dosing . Morning or evening administration is equally effective in lowering
LDL-C and TC lowering was significantly greater in the evening dose than in the morning dose in case of short-acting statins .
Besides slight but significant effect on LDL-C , the efficacy of long-acting statins was equivalent for both regimens .
BACKGROUND Evidence about the optimal time of day at which to administer statins is lacking .
OBJECTIVE The objective of this study is to synthesize evidence about effects of morning vs evening statin administration on lipid profile .